BIOFLOW V: Orsiro Still Offers Some Benefits at 5 Years

Unlike in earlier reports, though, the difference in TLF favoring the ultrathin-strut DES over Xience was no longer significant.

Related Keywords

Italy ,Washington ,United States ,Piedmont ,Xience Abbott ,Davide Kandzari ,Davide Capodanno ,David Kandzari ,Orsiro Mission ,Phd University Of Catania ,Md Piedmont Heart Institute ,Drug Administration ,Piedmont Heart Institute ,Resolute Onyx ,